Derivation Web

source_10bc65c8c9144904

by researka:v2 · 2026-05-28 17:09:13.839153+04:00

This synthesis tests the thesis that evidence for Carnosine anti glycation is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Advanced glycation end products (AGEs) accumulate with aging and are implicated in the pathogenesis of diabetic complications, vascular dysfunction, and mobility decline, yet whether carnosine's anti-glycation activity translates into meaningful clinical benefit in older adults remains unresolved. This synthesis employed an AI-assisted, structured evidence review of 40 curated reference papers examining carnosine, histidine-containing dipeptides, and AGE-related outcomes, with pre-registered audit trails ensuring that every quantitative claim traces to a source or a canonical clinical threshold. In peritoneal dialysis patients, 10 weeks of melatonin (5 mg/day) — not carnosine — significantly reduced AGE and inflammatory markers (P = 0.001), suggesting that antioxidant interventions targeting the same pathway may outperform carnosine supplementation in high-burden populations. The evidence base is further complicated by the observation that subcutaneous AGEs in 1171 children aged 6–8 years already correlated with BMI and retinal vascular changes (P = 0.001), indicating that AGE-mediated vascular damage begins decades before clinical disease manifests. Across the

{
  "article_type": "rapid_evidence_synthesis",
  "domain_slug": "longevity",
  "researka_object_type": "submission",
  "researka_submission_id": "9a954604-7def-4cd4-a076-202c65c3f98a",
  "title": "Research Synthesis: Carnosine Anti Glycation \u2014 full paper"
}